Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13733705 | 0.78 | MAPK1 (0.42) | GPR142MAPK1CYP3A4CHRM5ITK | |
| SCHEMBL12256553 | 0.78 | MAPK1 (0.45) | GPR142MAPK1CYP3A4CHRM5ITK | |
| SCHEMBL20671646 | 0.76 | RECQL (0.42) | GPR142MAPK1CYP3A4KMT2AMEN1 | |
| SCHEMBL22213802 | 0.75 | GPR142 (0.40) | GPR142MAPK1CYP3A4KMT2AMEN1 | |
| SCHEMBL16133689 | 0.74 | MAPT (0.43) | GPR142MAPK1CYP3A4KMT2AMEN1 | |
| SCHEMBL12017902 | 0.74 | ERCC1 (0.40) | GPR142MAPK1PDE7BCHRM5ITK | |
| SCHEMBL3326375 | 0.70 | HSD11B1 (0.63) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL31369367 | 0.69 | AGTR1 (0.38) | MAPK1CYP3A4KMT2AMEN1KDM4E | |
| SCHEMBL16598143 | 0.69 | SMN1; SMN2 (0.56) | CYP3A4KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL46652 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | GPR142 3517/4885MAPK1 1550/4885CYP3A4 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.